Crestone - CRS3123

Newer Clostridium difficile treatments involve lowering the production of the symptom-inducing toxins A and B produced by the C. diff as well as the antibacterial effect of removing the C. diff without eliminating the rest of the gut microbes. 

CRS3123 is a antibiotic that specifically inhibits the methionyl-tRNA synthase, an enzyme that stops C.diff toxin production and spore formation, and is sparing of the normal gut microbes. 

This is a phase 2 trial and is a randomized, double-blind, multicenter study to evaluate the safety and efficacy of CRS3123 by Crestone Inc. The results were compared with oral vancomycin in adults with recurrent Clostridium difficile infection. Preliminary results show potential effectiveness. 

We are currently recruiting people with primary and recurrent C. diff infection. Contact us to see if you are eligible.